TODAY'S MARKET INTELLIGENCE
Vbl Therapeutics-B Publishes Abstract on Obotalsimab (PD-L1/4-1BB Bispecific Antibody) Phase II Study in First-line NSCLC at WCLC
English summary
Vbl Therapeutics-B (09887) announced that the abstract for its Phase II clinical study of obotalsimab (LBL-024), a PD-L1/4-1BB bispecific antibody, in first-line non-small cell lung cancer (NSCLC) has been published on the WCLC website.
The English text is machine translated and may require verification against the Chinese version.
Browse today's intelligence